IL4 and chronic rhinosinusitis with nasal polyps: Dupilumab, which is a monoclonal antibody targeting the IL-4/IL-13 receptor, has been shown in a phase 3 trial involving 448 patients with CRSwNP to reduce IgE in nasal secretions, as well as serum total IgE [39].